New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 7, 2014
03:19 EDTBSXBoston Scientific acquires IoGyn
Boston Scientific has signed a definitive agreement to acquire IoGyn, a pre-commercial stage company. The transaction is expected to close within days. IoGyn has developed and received U.S. Food and Drug Administration, FDA, clearance for the Symphion System, a next generation system for hysteroscopic intrauterine tissue removal including fibroids and polyps. This acquisition enables the pairing of the Symphion System with the Boston Scientific Genesys HTA System for abnormal uterine bleeding, to create a compelling set of gynecologic surgery products.Prior to the acquisition, Boston Scientific held approximately 28% equity ownership, in addition to notes receivable of approximately $8M. Total consideration included a net cash payment of approximately $65M at closing to acquire the remaining 72% of IoGyn and repay outstanding debt. Boston Scientific expects the transaction to have an immaterial impact on its adjusted earnings per share in 2014 and 2015, and to be accretive starting in 2016. On a GAAP earnings per share basis, Boston Scientific expects the transaction to be slightly accretive in 2014 as a result of a non-cash acquisition-related gain on its previously held equity investment, immaterial in 2015 and 2016, and to be less accretive than adjusted earnings per share thereafter as a result of acquisition-related net charges and amortization, which will be determined following the closing.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
10:02 EDTBSXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:56 EDTBSXBoston Scientific initiated with a Hold at Needham
September 24, 2014
16:41 EDTBSXCourt says Boston Scientific breached license agreement
Boston Scientific disclosed in a regulatory filing that on September 24, following a jury verdict against Boston Scientific Corporation, the Montgomery County Circuit Court in Maryland entered a judgment that the company breached its license agreement with Mirowski Family Ventures and awarded damages of $308M. The company believes the facts and the law do not support the jury’s findings or the amount of the damages. The company plans to seek to overturn the judgment in post-trial motions with the Circuit Court and, if necessary, through the appeals process.
September 23, 2014
16:09 EDTBSXBoston Scientific enrolls first patients in U.S. trial of Lotus Valve System
Boston Scientific has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus Valve System in patients with severe aortic stenosis and who are considered to be at either high or extreme risk for surgical valve replacement. The Lotus Valve System is the first transcatheter aortic valve replacement device that is both fully repositionable and retrievable prior to release. The primary endpoints of the study are Safety; composite of all-cause mortality, stroke, life-threatening and major bleeding events, stage two or three acute kidney injury or major vascular complications at 30 days. Efficacy; composite of all-cause mortality, disabling stroke or moderate or greater paravalvular aortic regurgitation at one year following procedure.
September 17, 2014
07:43 EDTBSXBofA/Merrill to hold a conference
Subscribe for More Information
05:09 EDTBSXBoston Scientific receives CE Mark for Vercise DBS system
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use